<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548158" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548158/" /><meta name="ncbi_pagename" content="Nilutamide - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Nilutamide - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Nilutamide" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2017/07/05" /><meta name="citation_pmid" content="31643487" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548158/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Nilutamide" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2017/07/05" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548158/" /><meta name="description" content="Nilutamide is an oral nonsteroidal antiandrogen similar in structure to flutamide that is used widely in the therapy of prostate cancer and has been linked to rare instances of liver injury." /><meta name="og:title" content="Nilutamide" /><meta name="og:type" content="book" /><meta name="og:description" content="Nilutamide is an oral nonsteroidal antiandrogen similar in structure to flutamide that is used widely in the therapy of prostate cancer and has been linked to rare instances of liver injury." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548158/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Nilutamide/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548158/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D16BB04663EA100000000090D029E.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548158_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548158_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Nilotinib/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Nimesulide/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548158_"><span class="title" itemprop="name">Nilutamide</span></h1><p class="small">Last Update: <span itemprop="dateModified">July 5, 2017</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Nilutamide.OVERVIEW"><h2 id="_Nilutamide_OVERVIEW_">OVERVIEW</h2><div id="Nilutamide.Introduction"><h3>Introduction</h3><p>Nilutamide is an oral nonsteroidal antiandrogen similar in structure to flutamide that is used widely in the therapy of prostate cancer and has been linked to rare instances of liver injury.</p></div><div id="Nilutamide.Background"><h3>Background</h3><p>Nilutamide (nye loo' ta mide) is an anilide that blocks the binding of endogenous androgens to intracellular androgen receptors blocking their effects and is used to treat prostate cancer. Nilutamide has been shown to be effective in reducing pain and disease progression in metastatic prostate cancer when administered in conjunction with orchiectomy or other antiandrogen agents such as luteinizing hormone releasing hormone (LHRH) agonists. Nilutamide was approved for use in the United States in 1996. Current indications are limited to the therapy of metastatic prostate cancer in combination with orchiectomy. Nilutamide is available under the trade name Nilandron in 150 mg tablets, and the typical recommended dose is 300 mg daily starting at the time of orchiectomy with reduction of the dose to 150 mg daily one month later. Nilutamide is not approved for nor recommended for use in hyperandrogenic states such as hirsutism or acne. Common side effects include dizziness, impared vision, fatigue, nausea and anorexia.</p></div><div id="Nilutamide.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In large registration clinical trials, <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> elevations occurred in 2% to 33% of patients during nilutamide therapy. The elevations were usually mild, asymptomatic and transient, rarely requiring drug discontinuation. In rare instances, clinically apparent acute liver injury has occurred during nilutamide therapy, but the number of published cases are few, and the agent appears to be far less hepatotoxic than flutamide. In reported cases, the latency to onset averaged 2 to 4 months and the clinical pattern of enzyme elevations was typically hepatocellular, thus largely resembling flutamide induced liver injury. Signs of hypersensitivity and autoimmunity were not common.</p><p>Likelihood score: C (probable cause of clinically apparent liver injury).</p></div><div id="Nilutamide.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The mechanism of nilutamide hepatotoxicity is unknown, but toxic metabolites of the agent may induce oxidative stress or interfere with mitochondrial function.</p></div><div id="Nilutamide.Outcome_and_Management"><h3>Outcome and Management</h3><p>The mild <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> elevations during nilutamide therapy are usually self-limiting even with continuation of the medication. The rare instances of clinically apparent liver injury are usually self-limiting, but several fatal instances have been reported. Monitoring of liver tests is recommended before starting treatment and at regular intervals thereafter, particularly during the first 4 months of treatment. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.rechallenge/">Rechallenge</a> should be avoided. Patients with nilutamide hepatotoxicity should probably not receive flutamide and be given bicalutamide with caution.</p><p>Drug Class: <a href="/books/n/livertox/AntineoplasticAgents/">Antineoplastic Agents</a>, <a href="/books/n/livertox/Anti-androgens/">Antiandrogens</a></p></div></div><div id="Nilutamide.CASE_REPORTS"><h2 id="_Nilutamide_CASE_REPORTS_">CASE REPORTS</h2><div id="Nilutamide.Case_1._Acute_liver_failure_f"><h3>Case 1. Acute liver failure from nilutamide therapy.</h3><p>[Modified from: Marty F, Godart D, Doermann F, M&#x000e9;rillon H. [Fatal fulminating hepatitis caused by nilutamide. A new case] Gastroenterol Clin Biol 1996; 20: 710-1. French. <a href="https://www.ncbi.nlm.nih.gov/pubmed/8977826" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a>]</p><p>A 65 year old man with prostate cancer developed jaundice 8 weeks after starting nilutamide for prostate cancer. Nilutamide was stopped promptly, but he continued to worsen and developed mental confusion and was admitted to a hospital. On examination, he was markedly jaundiced and had stage 2 hepatic encephalopathy (asterixis and confusion). His past medical history was negative for liver disease and he had no risk factors for viral hepatitis and rarely drank alcohol. He had been diagnosed with prostate cancer and underwent orchiectomy 3 months previously and was treated postoperatively for 3 weeks with norfloxacin and prednisolone. Liver tests were reported to be normal before he was started on nilutamide (150 mg/day) and leuprolide (an LHRH analog: 3.75 mg intramuscularly each month). At the time that nilutamide was stopped 8 weeks later, serum bilirubin was 7.5 mg/dL, and it rose rapidly thereafter (Table). Tests for hepatitis A, B and C, EBV and CMV as well as for autoantibodies were negative. Abdominal ultrasound showed no evidence of biliary disease. He developed progressive mental obtundation, coagulopathy and, not being a candidate for emergency liver transplantation, died 16 days after onset of jaundice. Post mortem liver biopsy showed massive necrosis with minimal fibrosis.</p><div id="Nilutamide.Key_Points1"><h4>Key Points</h4><div id="Nilutamide.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548158/table/Nilutamide.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Nilutamide.T1_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Medication:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Nilutamide, 150 mg daily for 8 weeks</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Pattern:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Hepatocellular</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Severity:</td><td rowspan="1" colspan="1" style="vertical-align:top;">5+ (acute liver failure and death)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</td><td rowspan="1" colspan="1" style="vertical-align:top;">8 weeks</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Recovery:</td><td rowspan="1" colspan="1" style="vertical-align:top;">None</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Other medications:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Leuprolide. Prednisolone and norfloxacin 2 months previously</td></tr></tbody></table></div></div></div><div id="Nilutamide.Laboratory_Values1"><h4>Laboratory Values</h4><div id="Nilutamide.T2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548158/table/Nilutamide.T2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Nilutamide.T2_lrgtbl__"><table><thead><tr><th id="hd_h_Nilutamide.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Time After Starting</th><th id="hd_h_Nilutamide.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Time After Stopping</th><th id="hd_h_Nilutamide.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a><br /> (U/L)</th><th id="hd_h_Nilutamide.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Alk P (U/L)</th><th id="hd_h_Nilutamide.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a> (mg/dL)</th><th id="hd_h_Nilutamide.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Nilutamide.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Nilutamide.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Nilutamide.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Nilutamide.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Nilutamide.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Nilutamide.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Nilutamide.T2_1_1_1_1 hd_h_Nilutamide.T2_1_1_1_2 hd_h_Nilutamide.T2_1_1_1_3 hd_h_Nilutamide.T2_1_1_1_4 hd_h_Nilutamide.T2_1_1_1_5 hd_h_Nilutamide.T2_1_1_1_6" colspan="6" rowspan="1" style="vertical-align:top;">Nilutamide 150 mg daily after orchiectomy for prostate cancer</td></tr><tr><td headers="hd_h_Nilutamide.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">10 weeks</td><td headers="hd_h_Nilutamide.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Nilutamide.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">2360</td><td headers="hd_h_Nilutamide.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">231</td><td headers="hd_h_Nilutamide.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">7.5</td><td headers="hd_h_Nilutamide.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Nilutamide.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">12 weeks</td><td headers="hd_h_Nilutamide.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">2 weeks</td><td headers="hd_h_Nilutamide.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">1510</td><td headers="hd_h_Nilutamide.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">290</td><td headers="hd_h_Nilutamide.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">42.5</td><td headers="hd_h_Nilutamide.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Admission. Protime &#x0003c;15%</td></tr><tr><td headers="hd_h_Nilutamide.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">13 weeks</td><td headers="hd_h_Nilutamide.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">3 weeks</td><td headers="hd_h_Nilutamide.T2_1_1_1_3 hd_h_Nilutamide.T2_1_1_1_4 hd_h_Nilutamide.T2_1_1_1_5" colspan="3" rowspan="1" style="vertical-align:top;">Death from hepatic failure</td><td headers="hd_h_Nilutamide.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Nilutamide.T2_1_1_1_1 hd_h_Nilutamide.T2_1_1_1_2" colspan="2" rowspan="1" style="vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Nilutamide.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;40</b></td><td headers="hd_h_Nilutamide.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;350</b></td><td headers="hd_h_Nilutamide.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Nilutamide.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr></tbody></table></div></div></div><div id="Nilutamide.Comment1"><h4>Comment</h4><p>Despite stopping nilutamide when jaundice was first identified, this patient developed progressive hepatic failure and died within weeks of onset of liver injury. The latency (2 months), pattern of serum enzyme elevations (markedly hepatocellular), and lack of other obvious causes for liver injury (viral hepatitis, alcoholism, biliary disease, ischemia) points strongly to the role of nilutamide. The overall clinical characteristics of nilutamide hepatotoxicity resemble those of flutamide, but clinically apparent liver disease appears to be less common.</p></div></div><div id="Nilutamide.Case_2._Interstitial_pneumoni"><h3>Case 2. Interstitial pneumonitis and mild elevations in serum enzymes during nilutamide therapy.</h3><p>[Modified from: Gomez JL, Dupont A, Cusan L, Tremblay M, Tremblay M, Labrie F. Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report. Am J Med 1992; 92: 563-6. <a href="https://www.ncbi.nlm.nih.gov/pubmed/1580304" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a>]</p><p>A 69 year old man with prostate cancer developed shortness of breath and liver enzyme abnormalities 2 months after starting the combination of nilutamide and an luteinizing hormone releasing hormone (LHRH) analog. He had noticed progressive shortness of breath over the previous 4 weeks and was found to have tachypnea and abnormal chest x-ray findings suggestive of interstitial pneumonitis. Nilutamide was stopped. At the same time, blood test results showed mild elevations in <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> and alkaline phosphatase in comparison to pretreatment values. However, serum bilirubin levels were normal (Table). There was no eosinophilia and no signs of chronic liver disease or hepatic decompensation. Tests for viral hepatitis and autoantibodies were negative. A lung biopsy showed interstitial pneumonitis. In follow up, serum enzyme levels fell to pretreatment levels. He recovered slowly from the pulmonary complication. Flutamide was started after all test results returned to normal and was continued with no apparent toxic effects.</p><div id="Nilutamide.Key_Points2"><h4>Key Points</h4><div id="Nilutamide.T3" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548158/table/Nilutamide.T3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Nilutamide.T3_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Medication:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Nilutamide, 100 mg twice daily</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Pattern:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Hepatocellular</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Severity:</td><td rowspan="1" colspan="1" style="vertical-align:top;">1+ (enzyme elevations without jaundice)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</td><td rowspan="1" colspan="1" style="vertical-align:top;">2 months</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Recovery:</td><td rowspan="1" colspan="1" style="vertical-align:top;">75 days</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Other medications:</td><td rowspan="1" colspan="1" style="vertical-align:top;">LHRH agonist</td></tr></tbody></table></div></div></div><div id="Nilutamide.Laboratory_Values2"><h4>Laboratory Values</h4><div id="Nilutamide.T4" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548158/table/Nilutamide.T4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Nilutamide.T4_lrgtbl__"><table><thead><tr><th id="hd_h_Nilutamide.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Time After Starting</th><th id="hd_h_Nilutamide.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Time After Stopping</th><th id="hd_h_Nilutamide.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> (U/L)</th><th id="hd_h_Nilutamide.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Alk P (U/L)</th><th id="hd_h_Nilutamide.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a> (mg/dL)</th><th id="hd_h_Nilutamide.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Nilutamide.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Nilutamide.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Nilutamide.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">12</td><td headers="hd_h_Nilutamide.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">127</td><td headers="hd_h_Nilutamide.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.40</td><td headers="hd_h_Nilutamide.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Nilutamide.T4_1_1_1_1 hd_h_Nilutamide.T4_1_1_1_2 hd_h_Nilutamide.T4_1_1_1_3 hd_h_Nilutamide.T4_1_1_1_4 hd_h_Nilutamide.T4_1_1_1_5 hd_h_Nilutamide.T4_1_1_1_6" colspan="6" rowspan="1" style="vertical-align:top;">Nilutamide 100 mg every 12 hours and LHRH agonist started for prostate cancer</td></tr><tr><td headers="hd_h_Nilutamide.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">8 weeks</td><td headers="hd_h_Nilutamide.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Nilutamide.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">96</td><td headers="hd_h_Nilutamide.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">150</td><td headers="hd_h_Nilutamide.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.50</td><td headers="hd_h_Nilutamide.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Interstitial pneumonitis</td></tr><tr><td headers="hd_h_Nilutamide.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">18 weeks</td><td headers="hd_h_Nilutamide.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">10 weeks</td><td headers="hd_h_Nilutamide.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">13</td><td headers="hd_h_Nilutamide.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">132</td><td headers="hd_h_Nilutamide.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.40</td><td headers="hd_h_Nilutamide.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Nilutamide.T4_1_1_1_1 hd_h_Nilutamide.T4_1_1_1_2" colspan="2" rowspan="1" style="vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Nilutamide.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;35</b></td><td headers="hd_h_Nilutamide.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;130</b></td><td headers="hd_h_Nilutamide.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Nilutamide.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr></tbody></table></div></div></div><div id="Nilutamide.Comment2"><h4>Comment</h4><p>Interstitial pneumonitis is an uncommon but well established complication of nilutamide therapy. Symptoms and signs reverse slowly and only partially after therapy is stopped. This patient was also found to have minor <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> elevations but not clinically apparent liver disease during therapy. In most situations, such minor ALT elevations can be monitored without dose modification. The fact that this patient tolerated flutamide therapy without subsequent evidence of liver injury does not indicate that there is no cross reactivity in instances of clinically apparent hepatotoxicity between these two agents. Switching therapy to flutamide is not recommended for patients with clinically apparent liver injury from nilutamide.</p></div></div></div><div id="Nilutamide.PRODUCT_INFORMATION"><h2 id="_Nilutamide_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="Nilutamide.BPI" class="box"><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Nilutamide &#x02013; Nilandron&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antineoplastic Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=nilutamide" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="Nilutamide.CHEMICAL_FORMULA_AND_STRUCTUR"><h2 id="_Nilutamide_CHEMICAL_FORMULA_AND_STRUCTUR_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Nilutamide.T5" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548158/table/Nilutamide.T5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Nilutamide.T5_lrgtbl__"><table><thead><tr><th id="hd_h_Nilutamide.T5_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_Nilutamide.T5_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NO</th><th id="hd_h_Nilutamide.T5_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Nilutamide.T5_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Nilutamide.T5_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Nilutamide</td><td headers="hd_h_Nilutamide.T5_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135006493" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">63612-50-0</a></td><td headers="hd_h_Nilutamide.T5_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C12-H10-F3-N3-O4</td><td headers="hd_h_Nilutamide.T5_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><div class="graphic"><img src="/books/NBK548158/bin/Nilutamide_Structure.jpg" alt="Nilutamide chemical structure" /></div></td></tr></tbody></table></div></div></div><div id="Nilutamide.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Nilutamide_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 05 July 2017</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Nilutamide.R1">Zimmerman HJ. Hepatotoxic effects of oncotherapeutic and immunosuppressive agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, p. 699.<div><i>(Expert review of hepatotoxicity published in 1999, mentions that flutamide has led to instances of severe hepatic necrosis and fulminant hepatic failure).</i></div></div></li><li><div class="bk_ref" id="Nilutamide.R2">DeLeve LD. Antiandrogens. Cancer chemotherapy. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 612-3.<div><i>(Textbook on drug induced liver injury mentions that nilutamide has been implicated in causing at least four cases of acute hepatitis, two of which were fatal).</i></div></div></li><li><div class="bk_ref" id="Nilutamide.R3">Moy B, Lee RJ, Smith M. Hormone therapy in prostate cancer. Natural products in cancer chemotherapy: hormones and related agents. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1763-9.<div><i>(Textbook of pharmacology and therapeutics; discusses the role of androgen receptor blockers in prostate cancer including bicalutamide, flutamide and nilutamide).</i></div></div></li><li><div class="bk_ref" id="Nilutamide.R4">Hammel P, Ducreux M, Bismuth E, et al. [Nilutamide-induced acute hepatitis] Gastroenterol Clin Biol 1991; 15: 557. French.  [<a href="/pubmed/1916139" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1916139</span></a>]<div><i>(68 year old man with prostate cancer developed itching and then jaundice 4 months after starting nilutamide [bilirubin 8.2 mg/dL, ALT 22 times and Alk P 2 times ULN, eosinophils 800/&#x003bc;L], biopsy showed submassive necrosis; rapid improvement upon stopping with ultimate full recovery).</i></div></div></li><li><div class="bk_ref" id="Nilutamide.R5">Gomez JL, Dupont A, Cusan L, Tremblay M, Tremblay M, Labrie F. Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report. Am J Med 1992; 92: 563-6.  [<a href="/pubmed/1580304" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1580304</span></a>]<div><i>(69 year old man with prostate cancer developed pulmonary toxicity [interstitial pneumonitis] 2 months after starting nilutamide with concurrent minor enzyme abnormalities [bilirubin 0.50 mg/dL, ALT 96 U/L, Alk P 150 U/L], which resolved rapidly with stopping: Case 2).</i></div></div></li><li><div class="bk_ref" id="Nilutamide.R6">Pescatore P, Hammel P, Durand F, et al. [Fatal fulminant hepatitis induced by nilutamide (Anandron)] Gastroenterol Clin Biol 1993; 17: 499-501. French.  [<a href="/pubmed/8243938" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8243938</span></a>]<div><i>(69 year old man with prostate cancer underwent orchiectomy and developed jaundice 8 weeks after starting nilutamide [bilirubin 13.9 mg/dL, ALT 45 times ULN], with progressive liver failure and death within 2 weeks; autopsy showed massive necrosis).</i></div></div></li><li><div class="bk_ref" id="Nilutamide.R7">Bertagna C, De G&#x000e9;ry A, Hucher M, Fran&#x000e7;ois JP, Zanirato J. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients). Br J Urol 1994; 73: 396-402.  [<a href="/pubmed/8199827" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8199827</span></a>]<div><i>(Review of 7 randomized clinical trials of nilutamide in 1191 patients with prostate cancer showed improved pain and objective evidence of disease but not survival compared to placebo; no mention of hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Nilutamide.R8">Marty F, Godart D, Doermann F, M&#x000e9;rillon H. [Fatal fulminating hepatitis caused by nilutamide. A new case] Gastroenterol Clin Biol 1996; 20: 710-1. French.  [<a href="/pubmed/8977826" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8977826</span></a>]<div><i>(65 year old man with prostate cancer developed jaundice 8 weeks after starting nilutamide [bilirubin 9.3 mg/dL, ALT 2360 U/L, Alk P 231 U/L], with rapid progression to liver failure and death 3 weeks later: Case 1).</i></div></div></li><li><div class="bk_ref" id="Nilutamide.R9">Dijkman GA, Janknegt RA, De Reijke TM, Debruyne FM. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. J Urol 1997; 158: 160-3.  [<a href="/pubmed/9186345" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9186345</span></a>]<div><i>(Long term follow up of randomized clinical trials of nilutamide vs placebo after orchiectomy in 457 patients with prostate cancer; overall survival improved by 7 months, no new long term drug specific serious adverse event, no mention of hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Nilutamide.R10">McLeod DG. Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist 1997; 2: 18-27.  [<a href="/pubmed/10388026" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10388026</span></a>]<div><i>(Overview of the safety and side effects of the nonsteroidal antiandrogens; ALT elevations occur in 2-33% receiving nilutamide compared to 4-62% with flutamide; 5 cases of clinically apparent hepatitis have been reported due to nilutamide, compared to more than 50 with flutamide).</i></div></div></li><li><div class="bk_ref" id="Nilutamide.R11">Edouard A, Robinel R, Rat C, Lombard F, Lorinet C, Escarmant P. [Fatal fulminating hepatitis induced by nilutamide] Gastroenterol Clin Biol 2003; 27: 1170-1. French.  [<a href="/pubmed/14770126" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14770126</span></a>]<div><i>(67 year old man with prostate cancer developed jaundice 3 months after starting nilutamide [bilirubin 14.2 mg/dL, ALT 35 times and Alk P 1.5 times ULN, protime 42%], with progressive hepatic failure and death 4 weeks later).</i></div></div></li><li><div class="bk_ref" id="Nilutamide.R12">Thole Z, Manso G, Salgueiro E, Revuelta P, Hidalgo A. Hepatotoxicity induced by antiandrogens: a review of the literature. Urol Int 2004; 73: 289-95.  [<a href="/pubmed/15604569" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15604569</span></a>]<div><i>(Systematic review of the literature from the Spanish pharmacovigilance group; 21 reports on hepatotoxicity of cyproterone, 46 flutamide, 4 nilutamide and only 1 bicalutamide; 6 cases of hepatocellular carcinoma linked to cyproterone therapy).</i></div></div></li><li><div class="bk_ref" id="Nilutamide.R13">Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug-induced liver injury in the United States. Liver Transpl 2004; 10: 1018-23.  [<a href="/pubmed/15390328" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15390328</span></a>]<div><i>(Among ~50,000 liver transplants done in the United States between 1990 and 2002, 270 [0.5%] were done for drug induced acute liver failure, but no case was attributed to an antiandrogen, perhaps because patients with prostate cancer would not be eligible for liver transplantation).</i></div></div></li><li><div class="bk_ref" id="Nilutamide.R14">Manso G, Thole Z, Salgueiro E, Revuelta P, Hidalgo A. Spontaneous reporting of hepatotoxicity associated with antiandrogens: data from the Spanish pharmacovigilance system. Pharmacoepidemiol Drug Saf 2006; 15: 253-9.  [<a href="/pubmed/16294367" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16294367</span></a>]<div><i>(Analysis of spontaneous reporting to Spanish pharmacovigilance system found 88 cases of flutamide, 11 bicalutamide and 15 cyproterone hepatotoxicity, latency 3-6 months; 2 fatalities, both from flutamide; nilutamide not used in Spain).</i></div></div></li><li><div class="bk_ref" id="Nilutamide.R15">Bj&#x000f6;rnsson E, Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis 2006; 38: 33-8. (Survey of drug induced liver fatalities reported to WHO database between 1968-2003 revealed 4690 reports; flutamide ranked 11th with a total of 59 cases) [<a href="/pubmed/16054882" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16054882</span></a>]<div><i>.</i></div></div></li><li><div class="bk_ref" id="Nilutamide.R16">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34.  [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i>(Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008, none were attributed to an antiandrogen).</i></div></div></li><li><div class="bk_ref" id="Nilutamide.R17">Merwat SN, Kabbani W, Adler DG. Fulminant hepatic failure due to nilutamide hepatotoxicity. Dig Dis Sci 2009; 54: 910-3.  [<a href="/pubmed/18688719" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18688719</span></a>]<div><i>(76 year old man with prostate cancer developed abdominal pain followed by jaundice 6 weeks after starting nilutamide [bilirubin 25.8 mg/dL, ALT 1793 U/L, Alk P 231 U/L, INR 1.7], followed by progressive hepatic and multiorgan failure and death).</i></div></div></li><li><div class="bk_ref" id="Nilutamide.R18">Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-76.  [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, but none were attributed to antiandrogen therapies).</i></div></div></li><li><div class="bk_ref" id="Nilutamide.R19">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52.e7.  [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, one case was attributed to bicalutamide, but none to nilutamide or other antiandrogensl).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548158</span><span class="label">PMID: <a href="/pubmed/31643487" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643487</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Nilotinib/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Nimesulide/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548158&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548158/?report=reader">PubReader</a></li><li><a href="/books/NBK548158/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548158" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548158" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Nilutamide. [Updated 2017 Jul 5].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548158/pdf/Bookshelf_NBK548158.pdf">PDF version of this page</a> (115K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=nilutamide+AND+imidazolidines/AE+AND+Human%5BMH%5D+AND+(jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI+OR+hepatitis,+toxic%5BMH%5D)+AND+(%222006/01/01%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Nilutamide: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=nilutamide" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Nilutamide: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4865962" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4865962" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4865962" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643810" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Antiandrogens</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Antiandrogens<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/8997470" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Nilutamide: an antiandrogen for the treatment of prostate cancer.</a><span class="source">[Ann Pharmacother. 1997]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Nilutamide: an antiandrogen for the treatment of prostate cancer.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Dole EJ, Holdsworth MT. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Ann Pharmacother. 1997 Jan; 31(1):65-75. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/10388026" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer.</a><span class="source">[Oncologist. 1997]</span><div class="brieflinkpop offscreen_noflow">Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">McLeod DG. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Oncologist. 1997; 2(1):18-27. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/16153201" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.</a><span class="source">[BJU Int. 2005]</span><div class="brieflinkpop offscreen_noflow">A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Davis NB, Ryan CW, Stadler WM, Vogelzang NJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">BJU Int. 2005 Oct; 96(6):787-90. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/11744479" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Nilutamide: possible utility as a second-line hormonal agent.</a><span class="source">[Urology. 2001]</span><div class="brieflinkpop offscreen_noflow">Nilutamide: possible utility as a second-line hormonal agent.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Desai A, Stadler WM, Vogelzang NJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Urology. 2001 Dec; 58(6):1016-20. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643487" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643487" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=60468c124664552c12c3d0bc">Nilutamide - LiverTox</a><div class="ralinkpop offscreen_noflow">Nilutamide - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T15:41:55-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal106&amp;ncbi_phid=CE8D16BB04663EA100000000090D029E&amp;ncbi_session=CE8D16BB0468C121_2317SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548158%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548158&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548158/&amp;ncbi_pagename=Nilutamide - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D16BB0468C121_2317SID /projects/books/PBooks@9.2 portal106 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>